India's First Dengue Vaccine Is Here - But Can the Poor Actually Finish Both Doses?
India's dengue-vaccine milestone has arrived alongside two unresolved problems: Takeda's tiered global pricing may put Qdenga out of reach for slum residents with the worst Aedes exposure and its two-dose, three-month schedule is hardest to complete for the migrant workers who move between those exact high-risk settlements.